Replimune Group (NASDAQ:REPL) Trading 6.4% Higher – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) shot up 6.4% on Wednesday . The company traded as high as $12.07 and last traded at $12.17. 66,165 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 864,305 shares. The stock had previously closed at $11.44.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. BMO Capital Markets upped their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. lifted their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group boosted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Stock Performance

The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $913.40 million, a price-to-earnings ratio of -3.86 and a beta of 1.30. The stock has a 50 day moving average price of $12.68 and a two-hundred day moving average price of $12.09.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after buying an additional 1,655 shares during the period. Graham Capital Management L.P. lifted its position in Replimune Group by 6.1% in the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock valued at $365,000 after acquiring an additional 1,731 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Replimune Group by 7.2% in the 4th quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock worth $456,000 after purchasing an additional 2,525 shares during the period. Algert Global LLC increased its holdings in Replimune Group by 7.1% during the 4th quarter. Algert Global LLC now owns 45,820 shares of the company’s stock worth $555,000 after purchasing an additional 3,057 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Replimune Group by 24.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after purchasing an additional 3,177 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.